Jonathan W Friedberg, MD, MMSc
Bannerji R et al. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol 2022;9(5):e327-39. Abstract
Budde LE et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: Phase I dose-escalation study. J Clin Oncol 2022;40(5):481-91. Abstract
Caimi PF et al. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2022;22(6):790-800. Abstract
Duell J et al. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021;106(9):2417-26. Abstract
Hutchings M et al. Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A phase I trial. J Clin Oncol 2021;39(18):1959-70. Abstract
Kambhampati S et al. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood 2022;140(19):2024-36. Abstract
Nowakowski GS et al. ROBUST: A phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol 2021;39(12):1317-28. Abstract
Sehn LH et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort data. Blood Adv 2022;6(2):533-43. Abstract
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract
Loretta J Nastoupil, MD
Falchi L et al. Subcutaneous epcoritamab with rituximab + lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial. ASCO 2022;Abstract 7524.
Jurczak W et al. Coastal: A phase 3 study of the PI3K-delta inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin’s lymphoma (iNHL). Blood 2021;138(Supplement 1):2430. Abstract
Morschhauser F et al. Six-year results from RELEVANCE: Lenalidomide plus rituximab (R2) versus rituximab-chemotherapy followed by rituximab maintenance in untreated advanced follicular lymphoma. J Clin Oncol 2022;40(28):3239-45. Abstract
Morschhauser F et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21(11):1433-42. Abstract
Townsend W et al. Obinutuzumab plus chemotherapy demonstrates long-term benefit over rituximab plus chemotherapy in patients with previously untreated follicular lymphoma: Final analysis of the GALLIUM study. EHA2022;Abstract S206.
Zinzani PL et al. CHRONOS-3: Randomized phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma. EHA 2021;Abstract S211.
Sonali M Smith, MD
Abramson JS et al. Brentuximab vedotin plus adriamycin and dacarbazine in nonbulky limited-stage Hodgkin lymphoma: Results of a phase 2 trial. Blood Adv 2022;bloodadvances.2022008420. Abstract
Ansell SM et al. First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1. ASCO 2022;Abstract 7503.
Carlo-Stella C et al. S201: Camidanlumab tesirine: Updated efficacy and safety in an open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R CHL). HemaSphere 2022;6:102-3. Abstract
Evens AM et al. Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: A detailed analysis from the phase III ECHELON-1 study. Haematologica 2022;107(5):1086-94. Abstract
Fornecker L-M et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): A multicenter, open-label, randomized, phase II trial. J Clin Oncol 2022;[Online ahead of print]. Abstract
Herrera AF et al. Exploratory analysis of factors influencing efficacy and safety of camidanlumab tesirine: Data from the open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL). ASH 2022;Abstract 1594.
Lee HJ et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for early stage classic Hodgkin lymphoma: Interim efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part C). ASH 2022;Abstract 4230.
Kumar A et al. Brentuximab vedotin combined with chemotherapy in patients with newly diagnosed early-stage, unfavorable-risk Hodgkin lymphoma. J Clin Oncol 2021;39(20):2257-65. Abstract
Park SI et al. Frontline PET-directed therapy with brentuximab vedotin plus AVD followed by nivolumab consolidation in patients with limited stage Hodgkin lymphoma. ASH 2022;Abstract 728.
Timmerman J et al. Updated results from an open-label phase 1/2 study of favezelimab (anti–LAG-3) plus pembrolizumab in relapsed or refractory classical Hodgkin lymphoma after anti–PD-1 treatment. ASH 2022;Abstract 316.
Voorhees TJ et al. Pretherapy metabolic tumor volume is associated with response to CD30 CAR T cells in Hodgkin lymphoma. Blood Adv 2022;6(4):1255-63. Abstract
David G Maloney, MD, PhD
Abramson JS. Choosing a CAR for relapsed/refractory large B-cell lymphoma. Transplant Cell Ther 2022;28(10):621-2. Abstract
Barba P et al. YTB323 (rapcabtagene autoleucel) demonstrates durable efficacy and a manageable safety profile in patients with relapsed/refractory diffuse large B-cell lymphoma: Phase I study update. ASH 2022;Abstract 439.
Dreyling M et al. Long-term clinical outcomes and correlative efficacy analyses in patients (pts) with relapsed/refractory follicular lymphoma (r/r FL) treated with tisagenlecleucel in the Elara trial. ASH 2022;Abstract 608.
Fowler NH et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial. Nat Med 2022;28(2):325-32. Abstract
Kamdar M et al. Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): Results from the randomized phase 3 Transform study. ASH 2021;Abstract 91.
Jacobson CA et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. Lancet Onc 2022;23(1):91-103. Abstract
Neelapu SS et al. 3-year follow-up analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-hodgkin lymphoma (iNHL). ASH 2022;Abstract 4660.
Schuster SJ et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 2021;22(10):1403-15. Abstract
Wang M et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol 2022;[Online ahead of print]. Abstract
Brad S Kahl, MD
Cohen JB et al. Pirtobrutinib, a highly selective, non-covalent (Reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study. SOHO 2022;Abstract 133.
Martin T et al. Ciltacabtagene autoleucel, an anti–B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol 2022;[Online ahead of print]. Abstract
Song Y et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: Long-term efficacy and safety results from a phase 2 study. Blood 2022;139(21):3148-58. Abstract
Wang M et al. Primary results from the double-blind, placebo-controlled, phase III SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL). ASCO 2022;Abstract LBA7502.
Wang ML et al. Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma. N Engl J Med 2022;386(26):2482-94. Abstract